Clinical Advancements for the Treatment of Pancreatic Cancer


Program Dates: November 29th, 2019 - November 28th, 2021
Credits: 0.75 AMA PRA Category 1 Credits™


Clinical Advancements for the Treatment of Pancreatic Cancer

Program Overview

This continuing education program will highlight recent advances in the treatment of patients with pancreatic cancer. Dr. Eileen O’Reilly will review the clinical presentations of pancreatic cancer to improve diagnosis in the early stages and overall disease prognosis. Next, she will review the safety and efficacy data of current and emerging pharmacotherapies for metastatic pancreatic cancer. Finally, Dr. O’Reilly will discuss the importance of coordinating with the healthcare team to implement optimal treatment regimens for patients with metastatic pancreatic cancer. Upon completion of this activity, learners will gain further insight into how to better treat and manage their patients with pancreatic cancer.

Target Audience

Oncologists, primary care physicians, internists, nurses, PAs, NPs and other healthcare providers involved in the management of patients with pancreatic cancer

Agenda

I. Pancreatic Cancer: Improving Early Diagnosis & Overall Disease Prognosis
II. Analyzing the Safety & Efficacy of Pharmacotherapies for the Management of Metastatic Pancreatic Cancer
III. Coordinating with the Healthcare Team to Implement Optimal Treatment Regimens for Metastatic Pancreatic Cancer

Learning Objectives

  1. Discuss the clinical presentations of pancreatic cancer to improve diagnosis in early stages and overall disease prognosis
  2. Review safety and efficacy data of current and emerging pharmacotherapies for the management of metastatic pancreatic cancer
  3. Coordinate with the healthcare team to implement optimal treatment regimens for patients with metastatic pancreatic cancer

Faculty

Eileen M. O’Reilly, MD
Winthrop Rockefeller Endowed Chair in Medical Oncology
Co-Director, Medical Initiatives
David M. Rubenstein Center for Pancreatic Cancer Research
Section Head, Hepatopancreaticobilary & Neuroendocrine Cancers
Memorial Sloan Kettering Cancer Center
New York, New York

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Eileen M. O’Reilly, MD Consultant/Advisor: AstraZeneca Pharmaceuticals; Celgene Corporation; CytomX Therapeutics, Inc.; Eisai Co., Ltd.; Ipsen; Merck & Co., Inc.; Molecular Templates, Inc.; Polaris Inc.; Rafael Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB

Grant/Research Support: AstraZeneca Pharmaceuticals; Bristol-Myers Squibb Company; BioAtla Inc.; BioNTech; Celgene Corporation; Genentech, USA Inc.; Silenseed

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski; and Chelsey Benedek  hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Screen Shot 2018-12-11 at 12.19.42 PM

Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.

Financial Support

This activity has been supported by an independent educational grant from Celgene Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Celgene Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].

BUTTON

 

 

 

Provided by: AcademicCME-web

Leave a Reply

Your email address will not be published. Required fields are marked *